首页 > 最新文献

Lung India最新文献

英文 中文
Pleural effusion guidelines from ICS and NCCP Section 1: Basic principles, laboratory tests and pleural procedures. 第 1 部分:基本原理、实验室检测和胸膜手术。
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_33_24
Devasahayam J Christopher, Richa Gupta, Balamugesh Thangakunam, Jefferson Daniel, Surinder K Jindal, Surya Kant, Prashant N Chhajed, K B Gupta, Sahajal Dhooria, Sudhir Chaudhri, Dhruva Chaudhry, Dharmesh Patel, Ravindra Mehta, Rakesh K Chawla, Arjun Srinivasan, Arvind Kumar, Shakti K Bal, Prince James, Jebin S Roger, Avinash A Nair, S K Katiyar, Ritesh Agarwal, Raja Dhar, Ashutosh N Aggarwal, J K Samaria, Digambar Behera, Karan Madan, Raj B Singh, S K Luhadia, Nikhil Sarangdhar, George D' Souza, Amita Nene, Akhil Paul, Vimi Varghese, T V Rajagopal, M Arun, Shraddha Nair, Dhivya A Roy, Benjamin E Williams, Shona A Christopher, Dhanawade V Subodh, Nishant Sinha, Barney Isaac, Ashwin A Oliver, N Priya, Jedidiah Deva, Sujith T Chandy, Richu Bob Kurien

Pleural effusion is a common problem in our country, and most of these patients need invasive tests as they can't be evaluated by blood tests alone. The simplest of them is diagnostic pleural aspiration, and diagnostic techniques such as medical thoracoscopy are being performed more frequently than ever before. However, most physicians in India treat pleural effusion empirically, leading to delays in diagnosis, misdiagnosis and complications from wrong treatments. This situation must change, and the adoption of evidence-based protocols is urgently needed. Furthermore, the spectrum of pleural disease in India is different from that in the West, and yet Western guidelines and algorithms are used by Indian physicians. Therefore, India-specific consensus guidelines are needed. To fulfil this need, the Indian Chest Society and the National College of Chest Physicians; the premier societies for pulmonary physicians came together to create this National guideline. This document aims to provide evidence based recommendations on basic principles, initial assessment, diagnostic modalities and management of pleural effusions.

胸腔积液是我国的常见病,其中大多数患者需要进行侵入性检查,因为仅靠血液化验无法对其进行评估。其中最简单的是诊断性胸膜抽吸术,而医学胸腔镜等诊断技术的应用也比以往更加频繁。然而,印度大多数医生对胸腔积液采取经验性治疗,导致诊断延误、误诊和错误治疗引起的并发症。这种情况必须改变,迫切需要采用循证方案。此外,印度的胸膜疾病谱与西方不同,但印度医生却使用西方的指南和算法。因此,需要制定针对印度的共识指南。为了满足这一需求,印度胸科协会和全国胸科医师学会(肺科医师的主要协会)共同制定了这份全国指南。本文件旨在就胸腔积液的基本原则、初步评估、诊断方法和管理提供循证建议。
{"title":"Pleural effusion guidelines from ICS and NCCP Section 1: Basic principles, laboratory tests and pleural procedures.","authors":"Devasahayam J Christopher, Richa Gupta, Balamugesh Thangakunam, Jefferson Daniel, Surinder K Jindal, Surya Kant, Prashant N Chhajed, K B Gupta, Sahajal Dhooria, Sudhir Chaudhri, Dhruva Chaudhry, Dharmesh Patel, Ravindra Mehta, Rakesh K Chawla, Arjun Srinivasan, Arvind Kumar, Shakti K Bal, Prince James, Jebin S Roger, Avinash A Nair, S K Katiyar, Ritesh Agarwal, Raja Dhar, Ashutosh N Aggarwal, J K Samaria, Digambar Behera, Karan Madan, Raj B Singh, S K Luhadia, Nikhil Sarangdhar, George D' Souza, Amita Nene, Akhil Paul, Vimi Varghese, T V Rajagopal, M Arun, Shraddha Nair, Dhivya A Roy, Benjamin E Williams, Shona A Christopher, Dhanawade V Subodh, Nishant Sinha, Barney Isaac, Ashwin A Oliver, N Priya, Jedidiah Deva, Sujith T Chandy, Richu Bob Kurien","doi":"10.4103/lungindia.lungindia_33_24","DOIUrl":"10.4103/lungindia.lungindia_33_24","url":null,"abstract":"<p><p>Pleural effusion is a common problem in our country, and most of these patients need invasive tests as they can't be evaluated by blood tests alone. The simplest of them is diagnostic pleural aspiration, and diagnostic techniques such as medical thoracoscopy are being performed more frequently than ever before. However, most physicians in India treat pleural effusion empirically, leading to delays in diagnosis, misdiagnosis and complications from wrong treatments. This situation must change, and the adoption of evidence-based protocols is urgently needed. Furthermore, the spectrum of pleural disease in India is different from that in the West, and yet Western guidelines and algorithms are used by Indian physicians. Therefore, India-specific consensus guidelines are needed. To fulfil this need, the Indian Chest Society and the National College of Chest Physicians; the premier societies for pulmonary physicians came together to create this National guideline. This document aims to provide evidence based recommendations on basic principles, initial assessment, diagnostic modalities and management of pleural effusions.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"230-248"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of oxygenation indices in invasive mechanical ventilated adult patients. 有创机械通气成人患者氧合指数的相关性。
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_523_23
Ravi Jain, Ashish Jain, Srishti Jain, Rohit Jain, Puneet Panwar, Manish Goyal, Anand Kumar Jain, Munesh Meena, Priyamvada Gupta, Hetal Manghwani, Divyansh Gupta

Background: Mechanical ventilation is essential for managing acute respiratory failure, but traditional methods of assessing oxygenation, like the PaO2/FiO2 ratio, pose challenges due to invasiveness and cost.

Objective: This single-centre prospective observational study aimed to assess the potential of the non-invasive Oxygen Saturation Index (OSI), utilising SpO2 measurements, to diagnose hypoxemia in mechanically ventilated adults. The study sought to establish correlations between OSI, oxygenation index (OI), PaO2/FiO2 ratio and SpO2/FiO2 ratio.

Methods: From August 2022 to July 2023, data was collected from 1055 mechanically ventilated intensive care unit patients. Statistical analysis included correlation tests, receiver operating curve (ROC) analysis and cut-off value determination for hypoxemia diagnosis.

Results: We found that the P/F ratio had a statistically significant negative correlation with OI (correlation coefficient -0.832, P value: 0.000 in hypoxemic group and correlation coefficient -0.888, P value: 0.000 in the non-hypoxemic group), and OSI (correlation coefficient -0.746, P value: 0.000 in hypoxemic group and correlation coefficient -0.629, P value: 0.000 in non-hypoxemic group) and has a positive correlation with P/F ratio (correlation coefficient 0.92, P value: 0.000 in hypoxemic group and correlation coefficient -0.67, P value: 0.000 in non-hypoxemic group). OI and OSI had a statistically significant correlation (correlation coefficient 0.955, P value: 0.000 in hypoxemic group and correlation coefficient 0.815, P value: 0.000 in non-hypoxemic group). on ROC analysis P/F ratio was the most accurate in predicting hypoxia followed by OI and OSI. with a cut-off value, of OI being 7.07, and that for OSI being 3.90, at an 80% sensitivity level to diagnose hypoxemia.

Conclusion: OSI can serve as a dependable surrogate for OI, simplifying ARDS severity assessment. The P/F ratio is the most accurate predictor of hypoxia. Further research, especially in larger multicentre studies, is needed to validate these findings and explore the long-term clinical implications of using OSI for oxygenation monitoring in mechanically ventilated patients.

背景:机械通气是治疗急性呼吸衰竭的关键:机械通气对急性呼吸衰竭的治疗至关重要,但传统的氧饱和度评估方法(如PaO2/FiO2比值)因其侵入性和成本而面临挑战:这项单中心前瞻性观察研究旨在利用 SpO2 测量值评估无创氧饱和度指数 (OSI) 诊断机械通气成人低氧血症的潜力。该研究试图建立 OSI、氧饱和度指数(OI)、PaO2/FiO2 比值和 SpO2/FiO2 比值之间的相关性:方法:从 2022 年 8 月至 2023 年 7 月,收集了 1055 名机械通气重症监护病房患者的数据。统计分析包括相关性检验、接收者操作曲线(ROC)分析和低氧血症诊断临界值的确定:我们发现,P/F 比值与 OI(低氧血症组相关系数为 -0.832,P 值为 0.000;非低氧血症组相关系数为 -0.888,P 值为 0.000)和 OSI(低氧血症组相关系数为 -0.746,P 值为 0.000,非低氧血症组相关系数-0.629,P 值:0.000),并与 P/F 比值呈正相关(低氧血症组相关系数 0.92,P 值:0.000,非低氧血症组相关系数-0.67,P 值:0.000)。在 ROC 分析中,P/F 比值是预测缺氧最准确的指标,其次是 OI 和 OSI,OI 临界值为 7.07,OSI 临界值为 3.90,诊断低氧血症的灵敏度为 80%:结论:OSI 可作为 OI 的可靠替代指标,简化 ARDS 严重程度的评估。P/F比值是最准确的缺氧预测指标。还需要进一步的研究,尤其是更大规模的多中心研究,来验证这些发现,并探索使用 OSI 监测机械通气患者氧合情况的长期临床意义。
{"title":"Correlation of oxygenation indices in invasive mechanical ventilated adult patients.","authors":"Ravi Jain, Ashish Jain, Srishti Jain, Rohit Jain, Puneet Panwar, Manish Goyal, Anand Kumar Jain, Munesh Meena, Priyamvada Gupta, Hetal Manghwani, Divyansh Gupta","doi":"10.4103/lungindia.lungindia_523_23","DOIUrl":"10.4103/lungindia.lungindia_523_23","url":null,"abstract":"<p><strong>Background: </strong>Mechanical ventilation is essential for managing acute respiratory failure, but traditional methods of assessing oxygenation, like the PaO2/FiO2 ratio, pose challenges due to invasiveness and cost.</p><p><strong>Objective: </strong>This single-centre prospective observational study aimed to assess the potential of the non-invasive Oxygen Saturation Index (OSI), utilising SpO2 measurements, to diagnose hypoxemia in mechanically ventilated adults. The study sought to establish correlations between OSI, oxygenation index (OI), PaO2/FiO2 ratio and SpO2/FiO2 ratio.</p><p><strong>Methods: </strong>From August 2022 to July 2023, data was collected from 1055 mechanically ventilated intensive care unit patients. Statistical analysis included correlation tests, receiver operating curve (ROC) analysis and cut-off value determination for hypoxemia diagnosis.</p><p><strong>Results: </strong>We found that the P/F ratio had a statistically significant negative correlation with OI (correlation coefficient -0.832, P value: 0.000 in hypoxemic group and correlation coefficient -0.888, P value: 0.000 in the non-hypoxemic group), and OSI (correlation coefficient -0.746, P value: 0.000 in hypoxemic group and correlation coefficient -0.629, P value: 0.000 in non-hypoxemic group) and has a positive correlation with P/F ratio (correlation coefficient 0.92, P value: 0.000 in hypoxemic group and correlation coefficient -0.67, P value: 0.000 in non-hypoxemic group). OI and OSI had a statistically significant correlation (correlation coefficient 0.955, P value: 0.000 in hypoxemic group and correlation coefficient 0.815, P value: 0.000 in non-hypoxemic group). on ROC analysis P/F ratio was the most accurate in predicting hypoxia followed by OI and OSI. with a cut-off value, of OI being 7.07, and that for OSI being 3.90, at an 80% sensitivity level to diagnose hypoxemia.</p><p><strong>Conclusion: </strong>OSI can serve as a dependable surrogate for OI, simplifying ARDS severity assessment. The P/F ratio is the most accurate predictor of hypoxia. Further research, especially in larger multicentre studies, is needed to validate these findings and explore the long-term clinical implications of using OSI for oxygenation monitoring in mechanically ventilated patients.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"176-180"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing risk of infectious disease transmission at religious mass gatherings: Insights from survey, COVID-19 PCR, and antibody tests from Arbaeen walkers in 2020. 管理宗教集会中的传染病传播风险:从调查、COVID-19 PCR 和 2020 年 Arbaeen 步行者抗体检测中获得的启示。
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_431_23
Farah Al-Ansari, Basma Al-Ansari, Mohammed S Abdulzahra, Harunor Rashid, Grant A Hill-Cawthorne, Mohammad B Al-Ansari, Sabah M Al-Fatlaw, Mohammad Mawash, Mustafa Al Ansari, Katherine M Conigrave

Background: Arbaeen in Iraq has been one of the largest mass gatherings during the COVID-19 pandemic with 14.5 million attendees in 2020. We set out to assess the prevalence of current or past COVID-19 among 2020 Arbaeen participants, and establish associations between COVID-19 test results, symptoms, and known recent exposure.

Methods: This was a cross-sectional study involving participants who joined Arbaeen walk in Iraq in October 2020. COVID-19 PCR and/or rapid antibody test were conducted among consented participants. A short questionnaire was administered. Rapid antibody testing was done onsite. Nasal and throat swab samples were transferred to the laboratory for PCR testing.

Results: A total of 835 (88.3% male; 11.7% female) participants were recruited. The most common symptom overall was cough (9.6%) followed by sore throat, fever, and loss of taste/smell (6.6%, 5.5%, and 5.0%, respectively). One in five (20.3%) participants reported close contact with a confirmed COVID-19 case in the past 14 days. Of the 237 participants with a PCR test, 18 (7.6%) were positive. Of the 765 participants with rapid antibody test, 19.3% tested positive for IgM, 39.3% for IgG, and 16.4% for both. Approximately 40% of the participants had evidence of current or past COVID-19 infection based on antibody and PCR.

Conclusions: The almost 1 in 10 COVID-19 cases within such a multimillion person gathering, illustrates the difficulty in limiting the participation of infectious individuals in religious mass gatherings. There is a pressing need to explore measures to reduce the risk of transmission of infectious diseases at major mass gathering events.

背景:伊拉克的 Arbaeen 是 COVID-19 流行期间规模最大的群众集会之一,2020 年将有 1450 万人参加。我们旨在评估 2020 年 Arbaeen 参与者中当前或过去 COVID-19 的流行率,并建立 COVID-19 检测结果、症状和已知近期暴露之间的关联:这是一项横断面研究,涉及 2020 年 10 月参加伊拉克 Arbaeen 步行的参与者。在同意的参与者中进行 COVID-19 PCR 和/或快速抗体检测。进行了简短的问卷调查。快速抗体检测在现场进行。鼻腔和咽拭子样本被送往实验室进行 PCR 检测:共招募了 835 名参与者(88.3% 为男性;11.7% 为女性)。最常见的症状是咳嗽(9.6%),其次是喉咙痛、发烧和味觉/嗅觉丧失(分别为 6.6%、5.5% 和 5.0%)。五分之一(20.3%)的参与者表示在过去 14 天内曾与 COVID-19 确诊病例有过密切接触。在 237 名进行了 PCR 检测的参与者中,有 18 人(7.6%)的检测结果呈阳性。在接受快速抗体检测的 765 名参与者中,19.3% 的人 IgM 呈阳性,39.3% 的人 IgG 呈阳性,16.4% 的人 IgM 和 IgG 均呈阳性。根据抗体和 PCR 检测结果,约 40% 的参与者有当前或过去感染 COVID-19 的证据:在这样一个数百万人的集会中,几乎每 10 人中就有 1 例 COVID-19 感染者,这说明了限制感染者参与宗教集会的难度。我们迫切需要探索各种措施,以降低传染病在大型群众集会活动中传播的风险。
{"title":"Managing risk of infectious disease transmission at religious mass gatherings: Insights from survey, COVID-19 PCR, and antibody tests from Arbaeen walkers in 2020.","authors":"Farah Al-Ansari, Basma Al-Ansari, Mohammed S Abdulzahra, Harunor Rashid, Grant A Hill-Cawthorne, Mohammad B Al-Ansari, Sabah M Al-Fatlaw, Mohammad Mawash, Mustafa Al Ansari, Katherine M Conigrave","doi":"10.4103/lungindia.lungindia_431_23","DOIUrl":"10.4103/lungindia.lungindia_431_23","url":null,"abstract":"<p><strong>Background: </strong>Arbaeen in Iraq has been one of the largest mass gatherings during the COVID-19 pandemic with 14.5 million attendees in 2020. We set out to assess the prevalence of current or past COVID-19 among 2020 Arbaeen participants, and establish associations between COVID-19 test results, symptoms, and known recent exposure.</p><p><strong>Methods: </strong>This was a cross-sectional study involving participants who joined Arbaeen walk in Iraq in October 2020. COVID-19 PCR and/or rapid antibody test were conducted among consented participants. A short questionnaire was administered. Rapid antibody testing was done onsite. Nasal and throat swab samples were transferred to the laboratory for PCR testing.</p><p><strong>Results: </strong>A total of 835 (88.3% male; 11.7% female) participants were recruited. The most common symptom overall was cough (9.6%) followed by sore throat, fever, and loss of taste/smell (6.6%, 5.5%, and 5.0%, respectively). One in five (20.3%) participants reported close contact with a confirmed COVID-19 case in the past 14 days. Of the 237 participants with a PCR test, 18 (7.6%) were positive. Of the 765 participants with rapid antibody test, 19.3% tested positive for IgM, 39.3% for IgG, and 16.4% for both. Approximately 40% of the participants had evidence of current or past COVID-19 infection based on antibody and PCR.</p><p><strong>Conclusions: </strong>The almost 1 in 10 COVID-19 cases within such a multimillion person gathering, illustrates the difficulty in limiting the participation of infectious individuals in religious mass gatherings. There is a pressing need to explore measures to reduce the risk of transmission of infectious diseases at major mass gathering events.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"185-191"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Idiopathic nonspecific interstitial pneumonia: Waters remain murky…remember ABCDEFGHI. 特发性非特异性间质性肺炎:水仍然很浑浊......记住 ABCDEFGHI。
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_186_24
Sahajal Dhooria
{"title":"Idiopathic nonspecific interstitial pneumonia: Waters remain murky…remember ABCDEFGHI.","authors":"Sahajal Dhooria","doi":"10.4103/lungindia.lungindia_186_24","DOIUrl":"10.4103/lungindia.lungindia_186_24","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"169-171"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does serratiopeptidase prevent thoracic surgery in patients of hydropneumothorax of tubercular aetiology? 血清肽酶是否能预防结核性水胸腔积液患者的胸腔手术?
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_480_23
Siri Vineeth Anuraag Ganta, Kundan Mehta, Spandana Chaudary, M S Barthwal
{"title":"Does serratiopeptidase prevent thoracic surgery in patients of hydropneumothorax of tubercular aetiology?","authors":"Siri Vineeth Anuraag Ganta, Kundan Mehta, Spandana Chaudary, M S Barthwal","doi":"10.4103/lungindia.lungindia_480_23","DOIUrl":"10.4103/lungindia.lungindia_480_23","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"228"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A very rare case of anomalous systemic arterial supply to lung without sequestration. 一个非常罕见的肺部系统动脉供血异常病例,但没有栓塞。
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_40_24
Neeraj Sharma, Robin Choudhary, Samarjeet Singh, Yashvir Mathur
{"title":"A very rare case of anomalous systemic arterial supply to lung without sequestration.","authors":"Neeraj Sharma, Robin Choudhary, Samarjeet Singh, Yashvir Mathur","doi":"10.4103/lungindia.lungindia_40_24","DOIUrl":"10.4103/lungindia.lungindia_40_24","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"224-226"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aerosol drug therapy in critically ill patients (Aero-in-ICU study): A multicentre prospective observational cohort study. 危重病人的气溶胶药物治疗(重症监护病房气溶胶研究):一项多中心前瞻性队列观察研究。
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_580_23
Sanjay Singhal, Mohan Gurjar, Jyoti Narayan Sahoo, Sai Saran, Ruchi Dua, Alok Kumar Sahoo, Ankur Sharma, Sonika Agarwal, Arun Sharma, Pralay Shankar Ghosh, Parnandi Bhaskar Rao, Nikhil Kothari, Krupal Joshi, Kunal Deokar, Sudipta Mukherjee, Prakhar Sharma, Billa Ps Sreedevi, Prakash Sivaramakrishnan, Umadri Singh, Dhivya Sundaram, Avinash Agrawal, Chandan Dev Singh Katoch

Background: In recent years, a significant understanding of delivering optimal aerosol therapy and the availability of various drugs and devices have led to an increase in its use in clinical practice. There are only a few studies available regarding their use in critically ill patients from a few parts of the world. We aimed to study the practice pattern of aerosol therapy in critically ill patients from Indian intensive care units (ICUs).

Methods: After ethical approval, this multi-centric prospective observational study was performed over a study period of four weeks. Newly admitted adult patients considered who had an artificial airway and/or ventilation (including non-invasive). Patients were followed up for the next 14 days or until ICU discharge/death (whichever came first) for details of each aerosol therapy, including ongoing respiratory support, drug type, and aerosol-generating device.

Results: From the nine participating centers across India, 218 patients were enrolled. Of 218 enrolled patients, 72.48% received 4884 aerosols with 30.91 ± 27.15 (95%CI: 26.6-35.1) aerosols per patient over 1108 patient days. Approximately 62.7% during IMV, 30.2% during NIV, 2.3% in spontaneously breathing patients with an artificial airway during weaning, and 4.7% were given without an artificial airway after weaning or decannulation. In 59%, a single drug was used, and bronchodilators were the most frequent. The jet nebulizer was the most common, followed by the ultrasonic and vibrating mesh aerosol generator. The ventilator setting was changed in only 6.6% of the aerosol sessions with IMV and none with NIV.

Conclusion: Aerosol therapy is frequently used with a wide variation in practices; bronchodilators are the most commonly used drugs, and jet nebulizers are the most widely used.

背景:近年来,随着对最佳气溶胶疗法的深入了解以及各种药物和设备的出现,气溶胶疗法在临床实践中的应用越来越广泛。目前,世界上只有少数地区对危重病人使用气雾疗法进行了研究。我们旨在研究印度重症监护病房(ICU)重症患者的气雾疗法实践模式:在获得伦理批准后,我们进行了为期四周的多中心前瞻性观察研究。研究对象为新入院的成人患者,这些患者均使用人工气道和/或通气(包括无创通气)。在接下来的 14 天或重症监护室出院/死亡前(以先到者为准),对患者进行随访,以了解每种气溶胶疗法的详情,包括正在进行的呼吸支持、药物类型和气溶胶产生装置:印度的九个参与中心共招募了 218 名患者。在 218 名登记患者中,72.48% 的患者接受了 4884 次气雾剂治疗,每位患者在 1108 个患者日中接受了 30.91 ± 27.15(95%CI:26.6-35.1)次气雾剂治疗。约 62.7% 在 IMV 期间使用,30.2% 在 NIV 期间使用,2.3% 在断奶期间使用人工气道的自主呼吸患者中使用,4.7% 在断奶或停药后在没有人工气道的情况下使用。59%的患者使用单一药物,其中支气管扩张剂使用最多。最常用的是喷射式雾化器,其次是超声波和振动网状气溶胶发生器。在使用 IMV 的气雾治疗中,仅有 6.6% 的疗程改变了呼吸机设置,而在使用 NIV 的疗程中则没有:结论:气雾疗法使用频繁,但做法差异很大;支气管扩张剂是最常用的药物,而喷射式雾化器的使用最为广泛。
{"title":"Aerosol drug therapy in critically ill patients (Aero-in-ICU study): A multicentre prospective observational cohort study.","authors":"Sanjay Singhal, Mohan Gurjar, Jyoti Narayan Sahoo, Sai Saran, Ruchi Dua, Alok Kumar Sahoo, Ankur Sharma, Sonika Agarwal, Arun Sharma, Pralay Shankar Ghosh, Parnandi Bhaskar Rao, Nikhil Kothari, Krupal Joshi, Kunal Deokar, Sudipta Mukherjee, Prakhar Sharma, Billa Ps Sreedevi, Prakash Sivaramakrishnan, Umadri Singh, Dhivya Sundaram, Avinash Agrawal, Chandan Dev Singh Katoch","doi":"10.4103/lungindia.lungindia_580_23","DOIUrl":"10.4103/lungindia.lungindia_580_23","url":null,"abstract":"<p><strong>Background: </strong>In recent years, a significant understanding of delivering optimal aerosol therapy and the availability of various drugs and devices have led to an increase in its use in clinical practice. There are only a few studies available regarding their use in critically ill patients from a few parts of the world. We aimed to study the practice pattern of aerosol therapy in critically ill patients from Indian intensive care units (ICUs).</p><p><strong>Methods: </strong>After ethical approval, this multi-centric prospective observational study was performed over a study period of four weeks. Newly admitted adult patients considered who had an artificial airway and/or ventilation (including non-invasive). Patients were followed up for the next 14 days or until ICU discharge/death (whichever came first) for details of each aerosol therapy, including ongoing respiratory support, drug type, and aerosol-generating device.</p><p><strong>Results: </strong>From the nine participating centers across India, 218 patients were enrolled. Of 218 enrolled patients, 72.48% received 4884 aerosols with 30.91 ± 27.15 (95%CI: 26.6-35.1) aerosols per patient over 1108 patient days. Approximately 62.7% during IMV, 30.2% during NIV, 2.3% in spontaneously breathing patients with an artificial airway during weaning, and 4.7% were given without an artificial airway after weaning or decannulation. In 59%, a single drug was used, and bronchodilators were the most frequent. The jet nebulizer was the most common, followed by the ultrasonic and vibrating mesh aerosol generator. The ventilator setting was changed in only 6.6% of the aerosol sessions with IMV and none with NIV.</p><p><strong>Conclusion: </strong>Aerosol therapy is frequently used with a wide variation in practices; bronchodilators are the most commonly used drugs, and jet nebulizers are the most widely used.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"200-208"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Call to action: Addressing asthma diagnosis and treatment gaps in India. 行动呼吁:消除印度在哮喘诊断和治疗方面的差距。
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_518_23
Rajesh Swarnakar, Raja Dhar

In comparison to the worldwide burden of asthma, although India contributes to 13% of the total asthma prevalence, it has a threefold higher mortality rate and more than twofold higher DALYs, indicating a substantial gap in asthma diagnosis and treatment. Asthma causes significant suffering, affecting people's quality of life and draining the country's resources; therefore, we must devise ways and means to fill these gaps. The most successful and cost-efficient strategy to battle asthma is to form strong partnerships between patients, the general public, the government, the pharmaceutical industry and non-governmental organisations. This necessitates a comprehensive approach that involves raising awareness, developing universally applicable recommendations, increasing access to high-quality asthma care, and other measures. The purpose of this article was to review the existing scenario of asthma management in India and the factors that contribute to it and devise unique and all-encompassing strategies to fill these gaps.

与全世界的哮喘负担相比,虽然印度占哮喘总发病率的 13%,但其死亡率高出三倍,残疾调整寿命年数高出两倍多,这表明在哮喘诊断和治疗方面存在巨大差距。哮喘造成了巨大的痛苦,影响了人们的生活质量,消耗了国家的资源;因此,我们必须想方设法填补这些缺口。与哮喘病作斗争的最成功和最具成本效益的战略是在病人、公众、政府、制药业和非政府组织之间建立强有力的伙伴关系。这就需要采取全面的方法,包括提高认识、制定普遍适用的建议、增加获得高质量哮喘护理的机会以及采取其他措施。本文旨在回顾印度哮喘管理的现有情况和造成这种情况的因素,并制定独特而全面的战略来弥补这些不足。
{"title":"Call to action: Addressing asthma diagnosis and treatment gaps in India.","authors":"Rajesh Swarnakar, Raja Dhar","doi":"10.4103/lungindia.lungindia_518_23","DOIUrl":"10.4103/lungindia.lungindia_518_23","url":null,"abstract":"<p><p>In comparison to the worldwide burden of asthma, although India contributes to 13% of the total asthma prevalence, it has a threefold higher mortality rate and more than twofold higher DALYs, indicating a substantial gap in asthma diagnosis and treatment. Asthma causes significant suffering, affecting people's quality of life and draining the country's resources; therefore, we must devise ways and means to fill these gaps. The most successful and cost-efficient strategy to battle asthma is to form strong partnerships between patients, the general public, the government, the pharmaceutical industry and non-governmental organisations. This necessitates a comprehensive approach that involves raising awareness, developing universally applicable recommendations, increasing access to high-quality asthma care, and other measures. The purpose of this article was to review the existing scenario of asthma management in India and the factors that contribute to it and devise unique and all-encompassing strategies to fill these gaps.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"209-216"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RV in COPD - The complicated matters of the heart - Correlation of ECHO and biomarker with COPD severity and outcome. 慢性阻塞性肺病中的左心室--复杂的心脏问题--ECHO 和生物标志物与慢性阻塞性肺病严重程度和预后的相关性。
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_351_23
Rajesh Bhat, Sindhu Kamath, Arpit Jain, Vishak Acharya, Thomas Antony, Ramesh Holla, Abhavya Jha

Background: Patients with chronic obstructive pulmonary disease (COPD) have an increased risk of cardiovascular involvement, which is among the leading causes of morbidity and mortality worldwide. Echocardiography (ECHO) could be a reliable, non-invasive tool for predicting the risk of cardiovascular modalities in patients with COPD. Combining the ECHO parameters with highly selective cardiac troponin could predict the severity and outcome of patients with COPD.

Methods: This prospective observational study was conducted at a tertiary care hospital in South India. All patients who met the criteria were included. Patients with other concomitant chronic lung diseases were excluded. An echocardiographic examination was performed, and blood samples for hs-Tnt were taken on admission for patients admitted with COPD. Categorical variables were analyzed using Pearson's Chi-square test, and the T-test was used to compare the means. One-way analysis of variance (ANOVA) followed by the Bonferroni multiple comparison tests was done to compare different echo parameters concerning COPD severity.

Results: The mean tricuspid annulus plane systolic excursion (TAPSE) and right ventricle (RV) fraction area change (FAC) values were lower with the increase in the disease severity (P < 0.001). There was a significant increase in the mean systolic pressures in the right atrium and ventricle in patients with severe COPD (P < 0.001). The mean hs-TnT values were significantly higher in patients with severe COPD (18.86 ± 18.12) and correlated well with the increase in the severity of the disease (P < 0.001). Changes in the echo parameters, such as mean TAPSE and RV FAC values, negatively correlated with COPD severity. There was an increase in systolic pressure in both atria and ventricles with the progression of COPD. Troponin helped predict mortality during hospitalization.

Conclusion: Comprehensive echocardiographic parameters, such as TAPSE and RV FAC, help assess the disease's severity, predict mortality, and evaluate whether the proper ventricular function is reliable. Troponin is a valuable adjunct that is an independent and strong predictor of overall mortality in patients with COPD.

背景:慢性阻塞性肺疾病(COPD)患者受心血管疾病影响的风险增加,而心血管疾病是全球发病率和死亡率的主要原因之一。超声心动图(ECHO)是预测慢性阻塞性肺病患者心血管疾病风险的可靠、无创工具。将超声心动图参数与高选择性心肌肌钙蛋白相结合,可以预测慢性阻塞性肺病患者的病情严重程度和预后:这项前瞻性观察研究在印度南部的一家三级医院进行。所有符合标准的患者均被纳入研究。排除了合并其他慢性肺部疾病的患者。对慢性阻塞性肺病患者进行超声心动图检查,并在入院时抽取血液样本检测 hs-Tnt。分类变量的分析采用皮尔逊卡方检验(Pearson's Chi-square test),平均值的比较采用T检验。采用单因素方差分析(ANOVA)和Bonferroni多重比较检验来比较有关慢性阻塞性肺病严重程度的不同回声参数:结果:三尖瓣环平面收缩期平均偏移(TAPSE)和右心室(RV)分数面积变化(FAC)值随病情严重程度的增加而降低(P < 0.001)。严重慢性阻塞性肺病患者右心房和右心室的平均收缩压明显升高(P < 0.001)。重度慢性阻塞性肺病患者的 hs-TnT 平均值明显更高(18.86 ± 18.12),且与病情严重程度的增加密切相关(P < 0.001)。平均 TAPSE 值和 RV FAC 值等回声参数的变化与慢性阻塞性肺病的严重程度呈负相关。随着慢性阻塞性肺病病情的发展,心房和心室的收缩压都会升高。肌钙蛋白有助于预测住院期间的死亡率:结论:综合超声心动图参数,如 TAPSE 和 RV FAC,有助于评估疾病的严重程度、预测死亡率以及评估适当的心室功能是否可靠。肌钙蛋白是一种有价值的辅助指标,可独立且有力地预测慢性阻塞性肺病患者的总体死亡率。
{"title":"RV in COPD - The complicated matters of the heart - Correlation of ECHO and biomarker with COPD severity and outcome.","authors":"Rajesh Bhat, Sindhu Kamath, Arpit Jain, Vishak Acharya, Thomas Antony, Ramesh Holla, Abhavya Jha","doi":"10.4103/lungindia.lungindia_351_23","DOIUrl":"10.4103/lungindia.lungindia_351_23","url":null,"abstract":"<p><strong>Background: </strong>Patients with chronic obstructive pulmonary disease (COPD) have an increased risk of cardiovascular involvement, which is among the leading causes of morbidity and mortality worldwide. Echocardiography (ECHO) could be a reliable, non-invasive tool for predicting the risk of cardiovascular modalities in patients with COPD. Combining the ECHO parameters with highly selective cardiac troponin could predict the severity and outcome of patients with COPD.</p><p><strong>Methods: </strong>This prospective observational study was conducted at a tertiary care hospital in South India. All patients who met the criteria were included. Patients with other concomitant chronic lung diseases were excluded. An echocardiographic examination was performed, and blood samples for hs-Tnt were taken on admission for patients admitted with COPD. Categorical variables were analyzed using Pearson's Chi-square test, and the T-test was used to compare the means. One-way analysis of variance (ANOVA) followed by the Bonferroni multiple comparison tests was done to compare different echo parameters concerning COPD severity.</p><p><strong>Results: </strong>The mean tricuspid annulus plane systolic excursion (TAPSE) and right ventricle (RV) fraction area change (FAC) values were lower with the increase in the disease severity (P < 0.001). There was a significant increase in the mean systolic pressures in the right atrium and ventricle in patients with severe COPD (P < 0.001). The mean hs-TnT values were significantly higher in patients with severe COPD (18.86 ± 18.12) and correlated well with the increase in the severity of the disease (P < 0.001). Changes in the echo parameters, such as mean TAPSE and RV FAC values, negatively correlated with COPD severity. There was an increase in systolic pressure in both atria and ventricles with the progression of COPD. Troponin helped predict mortality during hospitalization.</p><p><strong>Conclusion: </strong>Comprehensive echocardiographic parameters, such as TAPSE and RV FAC, help assess the disease's severity, predict mortality, and evaluate whether the proper ventricular function is reliable. Troponin is a valuable adjunct that is an independent and strong predictor of overall mortality in patients with COPD.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"192-199"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive textbook of allergy - Striking the Right Balance. 过敏症综合教科书--《取得适当的平衡》。
IF 1.3 Q4 RESPIRATORY SYSTEM Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.4103/lungindia.lungindia_138_24
Rajesh Swarnakar
{"title":"Comprehensive textbook of allergy - Striking the Right Balance.","authors":"Rajesh Swarnakar","doi":"10.4103/lungindia.lungindia_138_24","DOIUrl":"10.4103/lungindia.lungindia_138_24","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 3","pages":"229"},"PeriodicalIF":1.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lung India
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1